The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Nov 3, 2022. Its latest SEC filing is a SC 13G/A from Jan 6, 2023.
10-Q for Q2 FY2023, filed Nov 3, 2022
The sections below describe the company as of the FY2022 annual report.
Sold heart pumps and related devices that supported circulation and oxygenation for patients treated by interventional cardiologists and cardiac surgeons in hospitals.
10-K for FY2022, filed May 20, 2022We are a provider of medical devices that provide circulatory support and oxygenation. We develop, manufacture and market proprietary…View ↗
Our strategic focus and the driver of our revenue growth is the market penetration of our family of Impella® heart pumps. Our Impella…View ↗
The Impella CP device provides blood flow of up to 4.3 liters of blood per minute and is primarily used by either interventional…View ↗
Hospitals and distributors paid for heart pumps and accessories when shipment or delivery terms were met. Customers also paid for maintenance contracts over their term and for maintenance calls when the service was provided.
10-K for FY2022, filed May 20, 2022The Company generates product revenue through the sale of Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5, Impella RP and…View ↗
Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and…View ↗
Service revenue is generally recognized over time as the services are rendered to the customer based on the extent of progress towards…View ↗
$1B
10-K for FY2022, filed May 20, 2022
$1B ↗
Sold products mainly to hospitals and distributors. Sales went through a direct sales force in the U.S. and Germany, and through direct sales and distribution agreements in other international markets.
10-K for FY2022, filed May 20, 2022
Yes. It kept 13 cents of every revenue dollar as net income in FY2022 and turned 24 cents into free cash flow.
10-K for FY2022, filed May 20, 2022
$140.7MView ↗
10-K for FY2022, filed May 20, 2022
$136.5MView ↗
10-K for FY2022, filed May 20, 2022
$249.6MView ↗
8-K, filed Dec 22, 2022
The Offer expired at 11:59 p.m., New York City time, on December 21, 2022 and was not extended. According to Parent, Merger Sub was advised…View ↗
Grew. Revenue grew 74% in 4 years, from $593.7M in FY2018 to $1B in FY2022, about 15% a year.
Competes with Cardiovascular Systems, Abbott Laboratories, Medtronic, Edwards Lifesciences, Boston Scientific, LivaNova, Terumo Heart, Teleflex, and Getinge
10-K for FY2022, filed May 20, 2022We are aware of other cardiac assist device research efforts in the U.S., Canada, Europe and Japan. In addition, there are a number of…View ↗
Loading...
